Stock Pitch Examples for Equity Research Interviews

In most investment banking interviews, the stock pitch is a side question. The interviewer wants to see that you follow the market, that you can form a view, that you understand what valuation is for. They'll ask one or two simple follow-ups and move on.

Equity research is a different animal. Here, the pitch isn't a side question. It's the main topic of conversation. An ER interviewer will likely ask you for multiple pitches, usually two to four of them, and they will expect you to know those companies very well. Not "I read the latest earnings summary" well. Coverage-analyst well: the segments, the margin structure, who the competitors are and how they're faring, what the street is modeling and where you think the street is wrong. You have been warned.

So the examples that work in an ER interview look different from the ones that get you through an IB round. They're deeper, they carry their own analysis, and every one of them is built to survive a long valuation-heavy interrogation. That's what this piece is about: what an equity research pitch actually sounds like when it's calibrated correctly, shown through worked examples you can model your own preparation on.

The mechanics of building a pitch, recommendation through closing, are covered in the complete stock pitch guide. I'll reference that skeleton lightly here, but the goal isn't to re-teach structure. It's to show you what raises the bar for ER.

In ER, you're being hired as an analyst, not interviewed as a candidate

Start with the volume problem. An IB interviewer asks for one pitch. An ER interviewer asks for two to four. That single difference changes how you prepare. You cannot fake depth across three names. If you cram one company the night before, you can usually bluff your way through a single IB follow-up. Try that across four companies in front of someone who covers the sector for a living, and the gaps show within ninety seconds.

This is why the best ER preparation isn't "pick three stocks." It's "pick a sector you find genuinely interesting and build real coverage of three or four names inside it." When your pitches share an industry, your knowledge compounds. The competitive dynamics you learned for the first name inform the second. You can speak to relative valuation across the group, which is exactly how a real research analyst thinks. The interviewer isn't testing whether you can recite a thesis. They're auditing whether you think like the person they're about to hire.

Keep each individual pitch tight, the same 1.5 to 2.5 minutes you'd use anywhere. The bar isn't length. It's that when they pull on any thread, there's something underneath.

What an equity-research-grade thesis actually sounds like

The make-or-break section of any pitch is the part where you explain what makes the company special and why the market has it wrong. In a PE or hedge fund interview, this is where you prove you can think like an investor. In equity research, it's the same. This is the part that matters most, and it's where ER candidates separate themselves.

Here's a hypothetical, labeled example to make the standard concrete. Imagine a mid-cap medical-device company. The street is modeling its EBITDA margin to hold flat at 25% as revenue grows toward $1.0b over the next three years. A weak ER thesis would say, "I think margins expand." A strong one sounds like this:

"The street models margins flat at 25% through their forecast because they're treating the new minimally-invasive platform as just another product line. I think that's wrong. That platform carries a structurally higher gross margin than the legacy catalog, and as it grows from roughly 10% of revenue today toward 30% by year three, mix alone lifts the blended EBITDA margin to about 30%. On the street's own $1.0b revenue figure, that's $300m of EBITDA versus their $250m. The street is missing $50m of EBITDA, and at the group's ~10x multiple, that's about $500m of enterprise value the market isn't pricing, or roughly six dollars a share."

(That example is hypothetical and the figures are illustrative.) Notice what it does. It names the specific thing the street has modeled incorrectly. It explains why they got it wrong, mix shift mistaken for a flat-margin product. It quantifies the gap. And it translates that gap into value per share. That's the texture of "analysis done on your end." You don't need a perfect target price; your interviewer isn't going to wait three months to see if you were right. You need a thesis that's robust, specific, and yours.

The best research analysts also tell a story. A company doesn't trade where it trades by accident. There's usually a narrative, a stretch of history that explains why sentiment soured and why the street is now anchored to the wrong expectation. Walking the interviewer through that arc, the way a company got cheap, makes the pitch memorable and sets up your "what they're missing" turn. As one rough template for the move:

"Going back a few years, the company embarked on an aggressive acquisition spree. The inorganic growth was impressive, but management overextended, started funding deals with equity, and missed earnings three times running. The street's view turned sour, and they're now modeling several quarters of tepid growth. But what they're missing is..."

That setup-then-reversal is the spine of a persuasive thesis. Aswath Damodaran is excellent at telling these stories through his analyses, and his YouTube videos are worth studying to see how a narrative and the numbers reinforce each other.

Build every pitch for the follow-up gauntlet

In an IB interview, you can expect one or two relatively simple follow-ups, usually just clarifying a point. They're testing conceptual understanding, not your investor mindset, and unless your thesis is confusing or plainly wrong, they don't dig much deeper.

ER is the opposite, and you should prepare for it specifically. After your pitch, expect numerous follow-ups on the justification behind your thesis, the comparable companies and precedent transactions you leaned on, the assumptions in your DCF, the competitive landscape and how competitors are faring, the total addressable market, and the reasoning behind your risks and mitigants. A significant share of those questions will land on valuation. This is the single clearest way ER raises the bar over IB, so put extra focus there.

What this means in practice: every claim in your pitch is a door, and you should assume the interviewer will open all of them. If you say the company should trade at 10x, be ready to defend why 10x and not 8x or 12x: which comps, what they're trading at, why your name deserves a premium or discount to them. If you cite a DCF, know your WACC, your terminal growth rate, and which assumption the valuation is most sensitive to. If you mention TAM, know how you sized it.

The strategic move here, and it's a good one, is to plant a number large enough to draw the follow-up you want. If your analysis produces a striking figure, say a free-cash-flow gap versus the street worth a couple billion dollars over your forecast, mention it deliberately. Your interviewer will almost certainly ask you to explain it. Because you raised it on purpose, you've steered them toward the one piece of analysis you've prepared most thoroughly, instead of leaving the follow-up to chance. You preempt the question and answer from strength.

A fully worked ER pitch

Here's a complete pitch for the hypothetical medical-device company above, taking it from recommendation through risk the way you'd deliver it in the room. Everything below is hypothetical and the numbers are illustrative, but they're internally consistent, which is exactly the discipline your own pitch needs.

"I'm pitching a long on the company, with an eighteen-month horizon and a target price of roughly $32, against a current price of $22, so call it about 45% upside. The stock is cheap because the street is anchored on a flat-margin story, and I think they've mis-modeled the mix.

Quick background: it's a mid-cap medical-device maker, around $800m of revenue and a 25% EBITDA margin today, net debt of about $400m, trading near 11 times EBITDA. Two years ago it over-invested in a legacy catalog, margins disappointed, and the street has modeled caution ever since.

My thesis is the new minimally-invasive platform. The street treats it as just another product line and holds the blended EBITDA margin flat at 25% on roughly $1.0b of revenue three years out. But that platform runs structurally higher gross margins than the legacy catalog. As it scales from about 10% of revenue today toward 30%, mix alone lifts the blended EBITDA margin to about 30%. That's $300m of EBITDA on the street's own revenue figure versus their $250m, a $50m gap. At the group's 10x multiple that's about $500m of enterprise value, or roughly six dollars a share, that the market isn't pricing.

On valuation, I get to my $32 target on 10 times my year-three EBITDA of $300m, which gives a $3.0b enterprise value, less $400m of net debt, over 80m shares. A DCF on the same margin path lands in a similar range, so the comps and the cash flows agree.

The catalyst is the next two or three earnings prints. As the platform's mix climbs, the margin inflection becomes visible in the reported numbers, and that's when the street's flat-margin model breaks. I'd expect the re-rating to play out over the back half of my horizon.

The main risk is reimbursement. A negative coverage decision on the new platform would slow adoption and delay the mix shift. I'm comfortable holding the long anyway, because the platform addresses procedures that are already widely reimbursed, and even on the street's flat-margin assumptions the stock isn't expensive, so I think the downside is limited while I wait for the thesis to prove out."

Run your eye back over that. It opens with a clear recommendation and a target. It contextualizes the business in two sentences. The thesis is specific, quantified, and tied to a mechanism. The valuation is defensible and cross-checked. The catalyst is linked to the horizon stated at the top. The risk comes with a mitigant. And several of those sentences are deliberate doors: the mix percentages, the 10x multiple, the DCF cross-check, the reimbursement risk. Each one invites a follow-up you'd want to get.

That's the bar. Now build three or four of them.

How this differs from the IB version

If you're also interviewing in banking, calibrate down, not up. The same medical-device pitch in an IB interview would stop after stating the two reasons margins inflect, and you'd say something like, "I've done an analysis on the margin path I'd be happy to walk through, but in short the street has mis-modeled the mix, and it's worth a material difference in free cash flow over my forecast." A price target range isn't strictly necessary in IB, though it helps to the extent it shows you can value a business. The follow-ups will be lighter, and the deep valuation interrogation mostly won't come.

In ER, you want the opposite instinct: more depth, more substantiation, more willingness to be pressed. The rigor ER expects mirrors what a hedge fund expects, which is why the two are often discussed together. For more on that closeness and on full pitches built to the same standard, see stock pitch examples for hedge fund interviews and what makes a hedge fund stock pitch different from an IB one.

Where to go from here

The fastest way to internalize this standard is to read real research-grade pitches and reverse-engineer how the analyst built conviction. For where to find them, see where to find real stock pitch examples online. To understand what's being graded as you deliver, see what interviewers actually look for in a stock pitch. And because ER lives in the catalyst, how to talk about catalysts in a stock pitch is worth a read before you finalize your names.